

patients transplanted with ACLF-3 and their 3-year post-LT survival increased over time: 2007–2009: 7 patients, 43% survival; 2010–2012: 20 patients, 60% survival; 2013–2015: 28 patients, 54% survival; 2016–2018: 36 patients, 83% survival (no significant difference in survival between the ACLF-3 and the non ACLF-3 group in the last period). This increase in the number of patients transplanted and in their post-LT three-year survival was not observed in the general population of patients transplanted without ACLF-3 (cf. Figure). A total of 12 ACLF-3 patients were transplanted with TAM scores >2. However, in the last period (2016–2018), in which both the number of patients transplanted with ACLF-3 and the post-LT survival were the highest, no patient was transplanted with a TAM score >2.

Conclusion: This study, which originates from the largest single center cohort of patients transplanted with ACLF-3, illustrates how gradually building a network of peripheral centers to refer critically ill cirrhotic patients to an expert ICU and LT center can lead to a dramatic increase in the number of patients transplanted with ACLF-3. It also shows that there is a learning curve when transplanting patients with ACLF-3 and that the implementation of the TAM score to help identify the optimal transplantability window at the time of organ proposal contributes to optimizing post-LT outcomes. The combination of these strategies can help centers increase the number of patients transplanted with ACLF-3 while reaching post-LT outcomes for these patients that are similar to those of non ACLF-3 patients.

OS011

Real-world evidence on long-term albumin treatment in patients with decompensated liver cirrhosis in Italy

Wim Laleman¹, Jonel Trebicka², Alastair O'Brien³, Paolo Caraceni⁴, Sandra Santos⁵, Tatiana Vilchez⁶, Kyle Rodney⁷, Sofia Schweiger⁸, Paolo Angeli⁹. ¹University Hospitals Leuven, Department of Gastroenterology and Hepatology, Section of Liver and Biliopancreatic Disorders, Leuven, Belgium; ²Goethe University Hospital Frankfurt, Translational Hepatology Department of Internal Medicine, Frankfurt, Germany; ³University College London, Institute for Liver and Digestive Health, London, United Kingdom; ⁴University of Bologna, Department of Medical and Surgical Science, Bologna, Italy; ⁵CSL Behring, Lisbon, Portugal; ⁶CSL Behring, Barcelona, Spain; ⁷Adivo Associates LLC, California, United States; ⁸Adivo Associates LLC, Buenos Aires, Argentina; ⁹University of Padova, Department of Medicine, Unit of Internal Medicine and Hepatology, Padova, Italy
Email: paolo.angeli54@gmail.com

Background and aims: Human albumin plays an important role in the management of patients with decompensated liver cirrhosis. Guidelines recommend short-term albumin in specific acute conditions, but clinical trial data have also shown benefits of long-term albumin (LTA) treatment. This study aimed to analyse real-world data on LTA treatment in patients with cirrhosis across Italy.

Method: Data from an independent audit platform was collected on patients with cirrhosis and ascites who received non-LTA, defined as standard medical treatment with diuretics and albumin only for acute indications, or LTA, with infusions at weekly intervals for ≥6 months. Audits were performed between 2018 and 2020, using institutional data and callbacks with healthcare professionals in Italy from 43 locations (hospitals, pharmacies and health units). Retrospective analysis was conducted on patient demographics, treatment dose and regimen, complication rates and hospitalisation outcomes.

Results: Data were captured for 6660 patients (non-LTA: 4305; LTA: 2355). Main etiologies of cirrhosis were alcoholic (33%), viral (29%) non-alcoholic steatohepatitis (30%) and other (7%). In LTA patients, the mean (range) treatment duration was 14 (6–36) months and initial dose was 87 (10–280) g/week, followed by 37 (10–60) g/week. The need for paracentesis (3.1 vs 6.2 per patient per year) and the incidence of refractory ascites (0.57 vs 0.71 per patient per year) were lower in LTA than in non-LTA patients. A lower incidence (episodes

per patient per year) of other major complications was also reported in LTA patients: spontaneous bacterial peritonitis (0.19 vs 0.09), hepatorenal syndrome (0.28 vs 0.16) and hepatic encephalopathy (0.40 vs 0.31). Hospitalisations were 2.40 and 2.85 per patient per year in LTA and non-LTA groups, respectively. Differences were maintained when comparing patients within age groups (<39, 40–59, ≥60 years).

Conclusion: These real-world data captured through an audit methodology indicate that Italian hepatologists consider LTA a valuable approach for the medical management of decompensated cirrhosis, as LTA is currently prescribed in a vast proportion of patients with ascites. Although the present study does not allow the comparison of the two groups, the lower incidence of paracentesis and complications observed in patients receiving LTA is consistent with the benefits documented by the ANSWER trial. Considering this, the cost-effectiveness of LTA and potential for reducing the economic burden upon healthcare systems should be assessed.

OS012

Impact of cirrhotic cardiomyopathy and severity of liver cirrhosis on the development of acute kidney injury

Simona Bota¹, Marcel Razpotnik¹, Philipp Wimmer², Michael Hackl², Gerald Lesnik³, Hannes Alber², Markus Peck-Radosavljevic¹. ¹Klinikum Klagenfurt am Wörthersee, Department of Internal Medicine and Gastroenterology (IMuG) and Emergency Medicine (ZAE), Klagenfurt, Austria; ²Klinikum Klagenfurt am Wörthersee, Department of Internal Medicine and Cardiology (IMuK), Klagenfurt, Austria; ³Klinikum Klagenfurt am Wörthersee, Institut for diagnostic and interventional Radiology, Klagenfurt, Austria
Email: bota_simona1982@yahoo.com

Background and aim: New criteria of cirrhotic cardiomyopathy (CCM) were published from a multidisciplinary consortium (Izzy et al. Hepatology 2019 Nov 11. doi: 10.1002/hep.31034) and define systolic dysfunction of the left ventricle as ejection fraction (EF) ≤50% and/or global longitudinal strain (GLS) <−18%, while the diastolic dysfunction is diagnosed when three of the following conditions are present: average E/e' >14, peak tricuspid regurgitation velocity >2.8 m/s, septal e' <7 cm/s, left atrial volume index >34 ml/m².

Our **aim** was to assess the influence of CCM, severity and etiology of liver cirrhosis on the development of acute kidney injury.

Method: Our prospective study included consecutive patients with liver cirrhosis without structural heart disease, arterial hypertension, HCC outside Milan criteria, portal vein thrombosis, presence of TIPS and with optimal acoustic echocardiography window. The patients were evaluated between 12/2018–11/2021 in our in- and out-patient Department. Conventional and speckle-tracking echocardiography (Vendor GE, EchoPAC PC software) were performed by a single investigator (EACVI TTE certified).

Acute kidney injury (AKIN) was defined according to the International Ascites Club as increase to serum creatinine of 0.3 mg/dL in <48 h or 50% increase in serum creatinine from baseline value within ≤3months.

The follow-up was performed until the patient was last seen or death.

Results: 412 cirrhotic patients were evaluated during the study period and 133 fulfilled the inclusion criteria and were included in the final analysis. The mean age of patients was 57.1 ± 10.2 years (60.1% males), 70.1% with alcoholic etiology and 48.1% with Child-Pugh A liver cirrhosis.

The median follow-up was 21 (0.5–36) months. Acute kidney injury was diagnosed in 26/133 (19.5%) of patients, while CCM (systolic and/or diastolic dysfunction) was present on 15% of patients.

The presence of acute kidney injury was correlated in univariate analysis with presence of CCM, Child-Pugh score, MELD score, alcoholic etiology of liver cirrhosis and prothrombin time (Table).

In multivariate logistic regression analysis only CCM and alcoholic etiology remained significantly associated with AKIN: CCM -OR = 13.6